260. Sitosterolemia Clinical trials / Disease details
Clinical trials : 12 / Drugs : 11 - (DrugBank : 3) / Drug target gene : 1 - Drug target pathway : 1
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2004-001580-22-DE (EUCTR) | 21/12/2004 | 20/10/2004 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | Homozygous Sitosterolemia | Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653 | MSD SHARP & DOHME GMBH | NULL | Not Recruiting | Female: yes Male: yes | 30 | Germany;United Kingdom | |||
| 2 | EUCTR2004-001580-22-GB (EUCTR) | 16/12/2004 | 24/02/2005 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Adding Ezetimibe 30 mg to an Ongoing Regimen of Ezetimibe 10 mg in Patients With Homozygous Sitosterolemia - Sitosterolemia High Dose Study | Homozygous Sitosterolemia | Trade Name: Ezetrol Product Name: Ezetrol Product Code: MK-0653 | Merck Sharp & Dohme Ltd | NULL | Not Recruiting | Female: yes Male: yes | 30 | Germany;United Kingdom |